supplied by www.ccc.ac.at

16 Einträge

Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.
Autoren Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Eberhardt WE, de Marinis F, Heeger S, Goddemeier T, O'Byrne KJ, Gatzemeier U
Erscheinungsdaten Lung cancer (Amsterdam, Netherlands). 2012 Apr 11. pii: S0169-5002(12)00121-3. doi: 10.1016/j.lungcan.2012.03.010
Publikations ID PMID: 22498112
 


EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
Autoren Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Störkel S, Schumacher KM, von Heydebreck A, Celik I, O'Byrne KJ
Erscheinungsdaten The Lancet. Oncology. 2011 Nov 4. pii: S1470-2045(11)70318-7. doi: 10.1016/S1470-2045(11)70318-7
Publikations ID PMID: 22056021
 


Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.
Autoren Brodowicz T, Ciuleanu T, Crawford J, Filipits M, Fischer JR, Georgoulias V, Gridelli C, Hirsch FR, Jassem J, Kosmidis P, Krzakowski M, Manegold Ch, Pujol JL, Stahel R, Thatcher N, Vansteenkiste J, Minichsdorfer C, Zöchbauer-Müller S, Pirker R, Zielinski CC
Erscheinungsdaten Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2011 Sep 22. pii: mdr381. doi: 10.1093/annonc/mdr381
Publikations ID PMID: 21940784
 


Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Autoren Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U
Erscheinungsdaten Lancet (London, England). 2009 May 4. pii: S0140-6736(09)60569-9. doi: 10.1016/S0140-6736(09)60569-9
Publikations ID PMID: 19410716
 


Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.
Autoren Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T, Cucevic B, Gyurkovits K, Ulsperger E, Jassem J, Grgic M, Saip P, Szilasi M, Wiltschke C, Wagnerova M, Oskina N, Soldatenkova V, Zielinski C, Wenczl M
Erscheinungsdaten Lung cancer (Amsterdam, Netherlands). 2006 Mar 29. pii: S0169-5002(06)00060-2. doi: 10.1016/j.lungcan.2006.01.006
Publikations ID PMID: 16569462
 


Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC).
Autoren Belani CP, Brodowicz T, Ciuleanu T, Kim JH, Krzakowski M, Laack E, Wu YL, Peterson P, Krejcy K, Zielinski C
Erscheinungsdaten Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 1. pii: 10.1200/jco.2009.27.18_suppl.cra8000
Publikations ID PMID: 27937591
 


Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study.
Autoren Ciuleanu TE, Brodowicz T, Belani CP, Kim J, Krzakowski M, Laack E, Wu Y, Peterson P, Adachi S, Zielinski CC
Erscheinungsdaten Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Jan 1. pii: 10.1200/jco.2008.26.15_suppl.8011
Publikations ID PMID: 27949013
 


FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC).
Autoren Pirker R, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Park K, Gatzemeier U, Bajeta E, Emig M, Pereira JR
Erscheinungsdaten Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Jan 1. pii: 10.1200/jco.2008.26.15_suppl.3
Publikations ID PMID: 27948496
 


Delay in time to worsening of symptoms (TWS) of advanced non-small cell lung cancer (NSCLC) using gemcitabine (gem) maintenance therapy.
Autoren Peterson P, Zwitter M, Krzakowski M, Wenczl M, Tzekova V, Ramlau R, Ciuleanu T, Liepa A, Zielinski C, Brodowicz T
Erscheinungsdaten Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Jan 1. pii: 10.1200/jco.2006.24.18_suppl.7140
Publikations ID PMID: 27953823
 


Phase III study comparing cisplatin/vinorelbine plus cetuximab versus cisplatin/vinorelbine as first-line treatment for patients with epidermal growth factor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC) (FLEX).
Autoren Von Pawel J, Park K, Pereira JR, Szczesna A, Yu C, Ganul VL, Krzakowski M, Roh JK, Pilz K, Pirker R
Erscheinungsdaten Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Jan 1. pii: 10.1200/jco.2006.24.18_suppl.7109
Publikations ID PMID: 27953547
 


Time interval between final protocol approval (FPA) and inclusion of the first patient into randomized clinical trials (RCTs) performed by the Central European Cooperative Oncology Group (CECOG): A 10-year experience.
Autoren Brodowicz T, Steiner I, Beslija S, Ciuleanu TE, Inbar M, Krzakowski M, Kahan Z, Tzekova V, Vrbanec D, Zielinski CC
Erscheinungsdaten Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 May 27. pii: 10.1200/jco.2009.27.15_suppl.6546
Publikations ID PMID: 27964062
 


Prognostic factors in advanced NSCLC: Experience from the FLEX trial.
Autoren Pirker R, Rodrigues-Pereira J, Szczesna A, Von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Emig M, Gatzemeier U
Erscheinungsdaten Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 1. pii: 10.1200/jco.2009.27.15_suppl.8083
Publikations ID PMID: 27962658
 


Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC).
Autoren Belani CP, Brodowicz T, Ciuleanu T, Kim JH, Krzakowski M, Laack E, Wu YL, Peterson P, Krejcy K, Zielinski C
Erscheinungsdaten Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 1. pii: 10.1200/jco.2009.27.15_suppl.cra8000
Publikations ID PMID: 27962042
 


First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Autoren Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV
Erscheinungsdaten The New England journal of medicine. 2018 Sep 25. doi: 10.1056/NEJMoa1809064
Publikations ID PMID: 30280641
 


Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.
Autoren Brodowicz T, Ciuleanu T, Crawford J, Filipits M, Fischer JR, Georgoulias V, Gridelli C, Hirsch FR, Jassem J, Kosmidis P, Krzakowski M, Manegold C, Pujol JL, Stahel R, Thatcher N, Vansteenkiste J, Minichsdorfer C, Zöchbauer-Müller S, Pirker R, Zielinski CC
Erscheinungsdaten Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Dec 4. pii: S0923-7534(19)34677-0. doi: 10.1093/annonc/mdr381
Publikations ID PMID: 32018580
 


Brief Report: Exploratory analysis of maintenance therapy in patients with extensive-stage small cell lung cancer treated first-line with atezolizumab plus carboplatin and etoposide.
Autoren Reck M, Mok TSK, Mansfield A, De Boer R, Losonczy G, Sugawara S, Dziadziuszko R, Krzakowski M, Smolin A, Hochmair M, Garassino MC, de Castro Junior G, Bischoff H, Lam S, Cardona A, Morris S, Liu SV
Erscheinungsdaten Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2022 Jun 25. pii: S1556-0864(22)00300-8. doi: 10.1016/j.jtho.2022.05.016
Publikations ID PMID: 35764236